NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
61 trialsNCT07416409 2026-02-18
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Completed
NCT02158507 2026-01-22
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
University of Alabama at Birmingham
Phase NA Completed
NCT04608409 2025-06-29
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
University of Kentucky
Phase 1 Completed
NCT00470704 2024-12-19
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01619111 2024-06-04
DETECT III
University of Ulm
Phase 3 Completed
NCT01300962 2023-12-04
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00841828 2023-03-31
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT00436566 2022-08-05
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT00952692 2021-12-20
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
Duke University
Phase 1/2 Completed
NCT00206427 2021-09-29
GW
Baylor Breast Care Center
Phase 2 Completed
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT02650752 2021-01-26
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00863122 2021-01-12
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT01875666 2020-09-04
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT00883688 2020-08-26
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00085020 2020-08-03
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT02362958 2020-07-15
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT00543504 2020-06-30
Bevacizumab in Multiple Phase I Combinations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00331630 2020-03-06
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00574171 2019-12-18
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
University of Wisconsin, Madison
Phase 2 Completed
NCT01827163 2019-12-18
Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01783756 2019-11-12
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Jonsson Comprehensive Cancer Center
Phase 1/2 Completed
NCT00820872 2019-10-21
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02073916 2019-04-16
STELA
The Methodist Hospital Research Institute
Phase 1 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01973660 2018-09-19
PAMELA
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT02015169 2018-01-17
Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis
Samsung Medical Center
Phase 2 Completed
NCT00404066 2017-12-22
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Stanford University
Phase 2 Completed
NCT02338245 2017-10-17
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
ASLAN Pharmaceuticals
Phase 2 Completed
NCT01275859 2017-08-29
Neo-All-In
Asan Medical Center
Phase 2 Completed
NCT00721630 2017-08-15
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00246753 2017-06-28
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00482391 2017-05-12
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00662636 2017-03-23
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Completed
NCT00379509 2017-03-21
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT02342587 2017-02-17
Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer
Samsung Medical Center
Phase 2 Completed
NCT01172223 2016-11-02
LAPADO
Sana-Klinikum Lichtenberg
Phase 1/2 Completed
NCT01454804 2016-04-13
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00973739 2016-03-22
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NYU Langone Health
Phase 2 Completed
NCT01426880 2016-02-15
GeparSixto
GBG Forschungs GmbH
Phase 2/3 Completed
NCT00567554 2016-02-10
GeparQuinto
GBG Forschungs GmbH
Phase 3 Completed
NCT00769470 2016-01-22
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
Translational Oncology Research International
Phase 2 Completed
NCT01087983 2015-11-11
Lapatinib With Sirolimus or Metformin
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00694252 2015-09-28
Lapatinib and Circulating Tumor Cells in Breast Cancer
University Hospital of Crete
Phase 2 Completed
NCT00632489 2015-06-08
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01218529 2014-12-31
Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT01262469 2014-12-16
GERICO09
UNICANCER
Phase 2 Completed
NCT00984425 2014-12-02
The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
Istituto Clinico Humanitas
Phase 1 Completed
NCT00313599 2014-07-02
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
University of California, San Francisco
Phase 1 Completed